Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

rHuEPO

Recombinant protein · Agonist · developed by Amgen

Phase 2 Most advanced trial
1 Registered trials

What is rHuEPO?

rHuEPO is a recombinant human erythropoietin given as a subcutaneous injection once weekly.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Recombinant protein
Mechanism
Agonist
Therapy area
Hematology, Oncology
Developer
Amgen
In trials of
SBFM
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07891377 Phase 2 Chemotherapy-induced Anemia Not yet recruiting SBFM

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Chemotherapy-induced AnemiaNon-Myeloid Malignancy

Sources

Updated Nov 1, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.